Differential induction of cytochrome P450 isoforms and peroxisomal proliferation by cyfluthrin in male Wistar rats.
A Anadón, M A Martínez, M Martínez, V Castellano, I Ares, A Romero, R Fernández, M R Martínez-Larrañaga
文献索引:Toxicol. Lett. 220(2) , 135-42, (2013)
全文:HTML全文
摘要
Cyfluthrin effects on in vivo drug metabolizing enzymes were evaluated using the oxidative substrate antipyrine. Antipyrine pharmacokinetics in plasma and urinary excretion of its major metabolites with and without cyfluthrin oral treatment (20mg/kg/day for 6 days) were investigated in rats. Cyfluthrin increased the apparent intrinsic clearance and decreased the antipyrine half-life at β phase. Cyfluthrin also increased the clearance of the antipyrine metabolites, norantipyrine, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine and the formation rate constants for each of the three metabolites measured in urine. These results suggest that cyfluthrin affects hepatic cytochrome P450 (CYP) system. In order to confirm, a second experiment was carried out. We evaluated the effects of repeated exposure to cyfluthrin on hepatic and renal CYP2E, CYP1A and CYP4A subfamilies and peroxisomal proliferation in rats following oral administration (10 and 20mg/kg/day for 6 days). At the highest dose, cyfluthrin increased renal and hepatic O-deethylation of ethoxyresorufin and O-demethylation of methoxyresorufin, metabolism mediated by the CYP1A subfamily. Liver and kidney were susceptible to cyfluthrin-dependent induction of 12- and 11-hydroxylation of lauric acid, suggesting CYP4A subfamily induction. Also cyfluthrin increased the β-oxidation of palmitoyl-coenzyme A and carnitine acetyltransferase activity, supporting cyfluthrin as a peroxisome proliferator. In conclusion, the demonstration that cyfluthrin induced hepatic CYP1A, CYP4A subfamilies and peroxisomal proliferation raises the possibility of cyfluthrin could produce changes in oxidative stress.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
相关化合物
相关文献:
2005-05-05
[J. Med. Chem. 48 , 3269-79, (2005)]
2013-01-01
[Undersea Hyperb. Med. 40(3) , 223-9, (2013)]
2012-12-07
[Neurosci. Lett. 531(2) , 160-5, (2012)]
2013-05-24
[Neurosci. Lett. 543 , 72-7, (2013)]
2013-09-01
[Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 113 , 43-51, (2013)]